Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

The study was carried out at 24 clinical sites across the UK and included 303 participants.

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1 ...

Traditional food logging apps offer feedback after the fact—Libre Assist 1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist 1 leverages AI to predict how food ...